Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Creating simple data classes in Java traditionally required substantial boilerplate code. Consider how we would represent Java’s mascots, Duke and Juggy: public class JavaMascot { private final String ...
Long-Term Support release, with features ranging from structured concurrency and compact object headers to ahead-of-time method profiling and JFR CPU-time profiling on Linux, is now generally ...
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
A new drug usually starts with a tragedy. Peter Ray knows that. Born in what is now Zimbabwe, the child of a mechanic and a radiology technician, Ray fled with his family to South Africa during the ...
Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results